Dutch Ophthalmic Research Center (International) B.V. has announced the launch of a significant enhancement to the EVA surgical system. This enhancement has been developed in close collaboration with users; it delivers both OR efficiency and surgical performance enhancements. The benefits of the enhancement include the following.
Firstly, the EVA footswitch has been completely redesigned, control of the EVA endolaser is now integrated into the main footswitch providing seamless switching between vitrectomy to laser and eliminating the need for a secondary laser pedal. As well as improving efficiency, any surgeon can operate independent of tech support when switching to laser. The new footswitch also has a range of ergonomic enhancements to ensure optimal surgeon comfort during longer procedures. These include buttons that can be reached without removing the foot from the pedal, a new heel rest to provide a more comfortable resting point and a lower angle of operation. It is also the first surgical system footswitch to feature interchangeable inlays (patent pending) allowing the surgeon to choose from 4 currently available options that can be easily switched. DORC also plans to offer customizable inlays at a future date.
Secondly, the EVA LED light source has been improved to provide at least 30% more light for 25/27g versus the current LED light. When combined with the enhanced 27g light fibres launched in 2018, this provides a further total enhancement in light output vs the previous technology available. This has been developed in response to demand for improved illumination from the growing number of surgeons working with 27g.
The CE mark was obtained in December 2018 and the enhancement is already in clinical use at several sites in Europe. It will be commercially available from March 2019 in US CE markets, with Japan soon to follow.
See the full news release from D.O.R.C.
Source: Dutch Ophthalmic Research Center